211 related articles for article (PubMed ID: 18234077)
1. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis.
Milici AJ; Kudlacz EM; Audoly L; Zwillich S; Changelian P
Arthritis Res Ther; 2008; 10(1):R14. PubMed ID: 18234077
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic treatment of a novel selective JAK3/JAK1/TBK1 inhibitor, CS12192, in rat and mouse models of rheumatoid arthritis.
Shan S; Zhou Y; Yu J; Yang Q; Pan D; Wang Y; Li L; Zhu J; Zhang Y; Huang S; Li Z; Ning Z; Xin L; Lu X
Int Immunopharmacol; 2019 Dec; 77():105914. PubMed ID: 31634789
[TBL] [Abstract][Full Text] [Related]
3. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
4. Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis.
Wei X; Wu J; Zhao G; Galdamez J; Lele SM; Wang X; Liu Y; Soni DM; Purdue PE; Mikuls TR; Goldring SR; Wang D
Mol Pharm; 2018 Aug; 15(8):3456-3467. PubMed ID: 29966420
[TBL] [Abstract][Full Text] [Related]
5. A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.
Stump KL; Lu LD; Dobrzanski P; Serdikoff C; Gingrich DE; Dugan BJ; Angeles TS; Albom MS; Ator MA; Dorsey BD; Ruggeri BA; Seavey MM
Arthritis Res Ther; 2011 Apr; 13(2):R68. PubMed ID: 21510883
[TBL] [Abstract][Full Text] [Related]
6. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).
Ghoreschi K; Jesson MI; Li X; Lee JL; Ghosh S; Alsup JW; Warner JD; Tanaka M; Steward-Tharp SM; Gadina M; Thomas CJ; Minnerly JC; Storer CE; LaBranche TP; Radi ZA; Dowty ME; Head RD; Meyer DM; Kishore N; O'Shea JJ
J Immunol; 2011 Apr; 186(7):4234-43. PubMed ID: 21383241
[TBL] [Abstract][Full Text] [Related]
7. Novel phosphoinositide 3-kinase δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis.
Boyle DL; Kim HR; Topolewski K; Bartok B; Firestein GS
J Pharmacol Exp Ther; 2014 Feb; 348(2):271-80. PubMed ID: 24244039
[TBL] [Abstract][Full Text] [Related]
8. Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis.
He L; Pei H; Lan T; Tang M; Zhang C; Chen L
Arch Pharm (Weinheim); 2017 Nov; 350(11):. PubMed ID: 28944566
[TBL] [Abstract][Full Text] [Related]
9. Glycogen synthase kinase-3beta inhibition attenuates the degree of arthritis caused by type II collagen in the mouse.
Cuzzocrea S; Mazzon E; Di Paola R; Muià C; Crisafulli C; Dugo L; Collin M; Britti D; Caputi AP; Thiemermann C
Clin Immunol; 2006 Jul; 120(1):57-67. PubMed ID: 16631408
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice.
Llop-Guevara A; Porras M; Cendón C; Di Ceglie I; Siracusa F; Madarena F; Rinotas V; Gómez L; van Lent PL; Douni E; Chang HD; Kamradt T; Román J
Arthritis Res Ther; 2015 Dec; 17():356. PubMed ID: 26653844
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
Tanaka Y; Maeshima K; Yamaoka K
Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i70-4. PubMed ID: 22460142
[TBL] [Abstract][Full Text] [Related]
12. An integrated network pharmacology approach reveals that Darutigenol reduces inflammation and cartilage degradation in a mouse collagen-induced arthritis model by inhibiting the JAK-STAT3 pathway.
Wang Y; Yan H; Zhao L; He XL; Bao TR; Sun XD; Yang YC; Zhu SY; Gao XX; Wang AH; Jia JM
J Ethnopharmacol; 2023 Oct; 314():116574. PubMed ID: 37160212
[TBL] [Abstract][Full Text] [Related]
13. Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms.
Thiel MJ; Schaefer CJ; Lesch ME; Mobley JL; Dudley DT; Tecle H; Barrett SD; Schrier DJ; Flory CM
Arthritis Rheum; 2007 Oct; 56(10):3347-57. PubMed ID: 17907188
[TBL] [Abstract][Full Text] [Related]
14. IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis.
Mori T; Miyamoto T; Yoshida H; Asakawa M; Kawasumi M; Kobayashi T; Morioka H; Chiba K; Toyama Y; Yoshimura A
Int Immunol; 2011 Nov; 23(11):701-12. PubMed ID: 21937456
[TBL] [Abstract][Full Text] [Related]
15. Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo
Raychaudhuri S; Abria C; Harmany ZT; Smith CM; Kundu-Raychaudhuri S; Raychaudhuri SP; Chaudhari AJ
Int J Rheum Dis; 2019 Dec; 22(12):2165-2169. PubMed ID: 31659868
[TBL] [Abstract][Full Text] [Related]
16. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.
Lin HS; Hu CY; Chan HY; Liew YY; Huang HP; Lepescheux L; Bastianelli E; Baron R; Rawadi G; Clément-Lacroix P
Br J Pharmacol; 2007 Apr; 150(7):862-72. PubMed ID: 17325656
[TBL] [Abstract][Full Text] [Related]
17. Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis.
Dowty ME; Jesson MI; Ghosh S; Lee J; Meyer DM; Krishnaswami S; Kishore N
J Pharmacol Exp Ther; 2014 Jan; 348(1):165-73. PubMed ID: 24218541
[TBL] [Abstract][Full Text] [Related]
18. Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis.
Yin Y; Chen CJ; Yu RN; Shu L; Wang ZJ; Zhang TT; Zhang DY
Bioorg Chem; 2020 May; 98():103720. PubMed ID: 32171982
[TBL] [Abstract][Full Text] [Related]
19. Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis.
Jüngel A; Ospelt C; Lesch M; Thiel M; Sunyer T; Schorr O; Michel BA; Gay RE; Kolling C; Flory C; Gay S; Neidhart M
Ann Rheum Dis; 2010 May; 69(5):898-902. PubMed ID: 19497915
[TBL] [Abstract][Full Text] [Related]
20. Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study.
Balagué C; Pont M; Prats N; Godessart N
Br J Pharmacol; 2012 Jun; 166(4):1320-32. PubMed ID: 22229697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
